AU Patent

AU2021320147A1 — Formulations of triphenyl calcilytic compounds

Assigned to Calcilytix Therapeutics Inc · Expires 2023-03-30 · 3y expired

What this patent protects

The present disclosure provides tablet formulations including a triphenyl calcilytic compound for the treatment of autosomal dominant hypocalcemia (ADH), where the compound is represented by formula (I): a solvate, a hydrate, a pharmaceutically acceptable salt, or a combination t…

USPTO Abstract

The present disclosure provides tablet formulations including a triphenyl calcilytic compound for the treatment of autosomal dominant hypocalcemia (ADH), where the compound is represented by formula (I): a solvate, a hydrate, a pharmaceutically acceptable salt, or a combination thereof.

Drugs covered by this patent

Patent Metadata

Patent number
AU2021320147A1
Jurisdiction
AU
Classification
—
Expires
2023-03-30
Drug substance claim
No
Drug product claim
No
Assignee
Calcilytix Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.